Kun Zhu

Kun Zhu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in The FASEB Journal
Verified
Journal Article
Closed access
KZKun Zhu
Kun Zhu
HZHanyue Zhang
Hanyue Zhang
YLYan Luan
Yan Luan
BHBaoqi Hu
Baoqi Hu
TSTu Shen
Tu Shen
XZXiaoyan Zheng
Xiaoyan Zheng

1 November 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KMKaige Ma
Kaige Ma
CAChanyuan An
Chanyuan An
MLMai Li
Mai Li
YZYuming Zhang
Yuming Zhang
MRMinghe Ren
Minghe Ren
KZKun Zhu
Kun Zhu
Purpose: β-amyloid overload-induced neuroinflammation and neuronal loss are key pathological changes that occur during the progression of Alzheimer’s disease (AD). Dexmedetomidine (Dex) exhibits neuroprotective and anti-inflammatory effects on the nervous system. However, the effect of Dex in AD mice remains unclear, and its neuroprotective regulatory mechanism requires further investigation. This study aimed to reveal how Dex protects against Aβ induced neuropathological changes and behavior dysfunction in AD mice. Methods: An AD mouse model was established by the injection of Aβ into the brains of mice, followed by intraperitoneal injection with Dex. CXCL2 overexpression and Yohimbine, a Dex inhibitor, were used to investigate the role of Dex and CXCL2 in the regulation of neuronal loss, cognitive decline, and anxiety-like behavior in AD mice. Behavioral tests were performed to evaluate the cognitive and anxiety status of the mice. Nissl staining and immunofluorescence experiments were conducted to evaluate the status of the hippocampal neurons and astrocytes. qRT-PCR was performed to detect the expression of CXCL2, IL-1β, INOS, SPHK1, Bcl2, IFN-γ, and Caspase 1. The malondialdehyde (MDA) level was detected using an ELISA kit. Terminal TUNEL and Fluoro-Jade C (FJC) staining were used to measure the cell apoptosis rate. Results: In AD mice, cognitive decline and anxiety-like behaviors were significantly improved by the Dex treatment. The number of neurons was increased in mice in the Dex + AD group compared to those in the AD group, and the number of astrocytes was not significantly different between the two groups. CXCL2, IL-1β, iNOS, and SPHK1 levels were significantly lower in Dex-treated AD mice than those in AD mice. Overloading of CXCL2 or Yohimbine reversed the protective effect of Dex on neuron number and cognitive and anxiety symptoms in AD mice. Conclusion: Our results suggest that Dex exerts neuroprotective effects by downregulating CXCL2. Dex shows potential as a therapeutic drug for AD.

31 January 2025 in The FASEB Journal
Verified
Journal Article
Closed access
KZKun Zhu
Kun Zhu
SSShirui Sun
Shirui Sun
ZLZepeng Li
Zepeng Li
GDGe Deng
Ge Deng
YGYingcong Guo
Yingcong Guo
Chenguang DingChenguang Ding
Chenguang Ding

28 August 2025 in Physica Medica
Verified
Journal Article
Closed access
XZXiaoyan Zheng
Xiaoyan Zheng
QTQi Tian
Qi Tian
RLRunying Li
Runying Li
YWYubin Wang
Yubin Wang
WZWeishan Zhang
Weishan Zhang
KZKun Zhu
Kun Zhu